Get started
Author

Zhiyu Liang

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study
2023 · Stephen Opat, Alessandra Tedeschi, et al. · Blood Advances · 47
PDF
Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
2022 · Stephen Opat, Alessandra Tedeschi, et al. · Blood · 7
Immunoglobulin isotype switch after anti-BCMA CAR T-cell therapy for relapsed or refractory multiple myeloma
2021 · Zhiyu Liang, Ping Li, et al. · Blood Advances · 6
PDF
Association of Cerebral Hemodynamics and Cognitive Function in Adult Patients with Moyamoya Disease: A Three-Dimensional Pseudo-Continuous Arterial Spin Labeling Study
2023 · Xiangyue Zha, Zhiyu Liang, et al. · World Neurosurgery · 4
Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
2022 · Huilai Zhang, Keshu Zhou, et al. · Blood · 4
Effects of leukotriene D4 nasal challenge on bronchial responsiveness and inflammation in asthmatic patients with allergic rhinitis
2017 · Zheng Zhu, Yanqing Xie, et al. · Journal of Thoracic Disease · 4
PDF
Efficacy and safety of angiogenesis inhibitors combined with poly ADP ribose polymerase inhibitors in the maintenance treatment of advanced ovarian cancer: a meta-analysis
2024 · Renming Huang, Feng Ji, et al. · Frontiers in Oncology · 3
PDF
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.
2023 · Caixia Li, Jia Wei, et al. · Journal of Clinical Oncology · 1
Zanubrutinib monotherapy in CD79B ‐mutated relapsed or refractory diffuse large B‐cell lymphoma: A multicenter Phase 2 study
2026 · Li Wang, Keshu Zhou, et al. · HemaSphere
PDF
P626: a Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients With Mature B-cell Malignancies
2023 · Caixia LI, Jia Wei, et al. · HemaSphere
P1136: First Interim Analysis of a Phase 1 Study of Zanubrutinib Plus Lenalidomide in Patients With Relapsed/refractory Diffuse Large B-cell Lymphoma
2023 · Huilai Zhang, Ying Cheng, et al. · HemaSphere
P1084: Long-term Efficacy and Safety of Zanubrutinib (zanu) in Patients (pts) With Relapsed/refractory (r/r) Marginal Zone Lymphoma (mzl): Final Analysis of the Magnolia (bgb-3111-214) Trial
2023 · Stephen Opat, Alessandra Tedeschi, et al. · HemaSphere
First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
2023 · Huilai Zhang, Ying Cheng, et al. · Journal of Clinical Oncology
PDF
Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial
2023 · Stephen Opat, Alessandra Tedeschi, et al. · Transplantation and Cellular Therapy
Works count: 14
Citation count: 76
H-index: 4
I10-index: 1
Year
Topic
Type